Literature DB >> 17368178

Conservative mutageneic perturbations of amino acids connecting helix 12 in the 1alpha,25(OH)2-D3 receptor (VDR) to the ligand cause significant transactivational effects.

Craig M Bula1, June E Bishop, Anthony W Norman.   

Abstract

The positioning of helix 12 activation domain of nuclear receptor proteins is critically important for gene regulation. Perturbations of the helix 12 by larger analogs may alter interactions with transcriptional machinery which might give rise to selectivity. To explore the topology of the ligand binding pocket and how the bound ligand conceivably gives rise to altered transcriptional efficiencies, we have targeted 4 hydrophobic residues which contact the 25-carbon of the ligand, 1alpha,25(OH)(2)-vitamin D(3), and made a series of 13 mutants. Substitution of a smaller hydrophobic residue was poorly tolerated compared to a larger one for transactivation. The larger amino acids are likely better tolerated by promoting stronger Van der Waals forces with the ligand. Valine-418 mutants demonstrated an extreme example of this observation with mutation to leucine being transactivationally unaffected with alanine being the most affected of all single mutants. V418L resulted in a 1.3-fold increase in EC(50) for 1,25-D mediated transactivation whereas V418A resulted in a 53-fold increase when compared to wildtype VDR. Importantly, this difference is not explained by ligand binding data but by differential VDR protease sensitivity implying that V418L-VDR mutation assumes a better conformational interaction surface for coactivator than V418A. Importantly, the V418 location may accommodate larger sidechains and may even enhance the interaction with specific nuclear coactivators.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17368178      PMCID: PMC1920180          DOI: 10.1016/j.jsbmb.2006.12.043

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  9 in total

1.  The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand.

Authors:  N Rochel; J M Wurtz; A Mitschler; B Klaholz; D Moras
Journal:  Mol Cell       Date:  2000-01       Impact factor: 17.970

2.  Biomedicine. Defining the "S" in SERMs.

Authors:  Benita S Katzenellenbogen; John A Katzenellenbogen
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

3.  Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid.

Authors:  J P Renaud; N Rochel; M Ruff; V Vivat; P Chambon; H Gronemeyer; D Moras
Journal:  Nature       Date:  1995-12-14       Impact factor: 49.962

4.  Different positioning of the ligand-binding domain helix 12 and the F domain of the estrogen receptor accounts for functional differences between agonists and antagonists.

Authors:  M Nichols; J M Rientjes; A F Stewart
Journal:  EMBO J       Date:  1998-02-02       Impact factor: 11.598

5.  Differential interaction of 1alpha,25-dihydroxyvitamin D3 analogues and their 20-epi homologues with the vitamin D receptor.

Authors:  Y Y Liu; E D Collins; A W Norman; S Peleg
Journal:  J Biol Chem       Date:  1997-02-07       Impact factor: 5.157

6.  Functional conformations of the nuclear 1alpha,25-dihydroxyvitamin D3 receptor.

Authors:  S Nayeri; C Carlberg
Journal:  Biochem J       Date:  1997-10-15       Impact factor: 3.857

7.  Molecular determinants for the tissue specificity of SERMs.

Authors:  Yongfeng Shang; Myles Brown
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

8.  The high affinity ligand binding conformation of the nuclear 1,25-dihydroxyvitamin D3 receptor is functionally linked to the transactivation domain 2 (AF-2).

Authors:  S Nayeri; J P Kahlen; C Carlberg
Journal:  Nucleic Acids Res       Date:  1996-11-15       Impact factor: 16.971

9.  The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen.

Authors:  A K Shiau; D Barstad; P M Loria; L Cheng; P J Kushner; D A Agard; G L Greene
Journal:  Cell       Date:  1998-12-23       Impact factor: 41.582

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.